Clinical Trial Update: Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safety and effectiveness of Lutetium-177 dotatate for metastatic prostate cancer with neuroendocrine differentiation;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostate Neuroendocrine Carcinoma
• Prostate Small Cell Neuroendocrine Carcinoma

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma | Phase 2 | Status: RECRUITING